CG Oncology Inc
NASDAQ:CGON
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.84
47.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CGON stock under the Base Case scenario is 56.11 USD. Compared to the current market price of 35.01 USD, CG Oncology Inc is Undervalued by 38%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
CG Oncology Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CGON cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
CG Oncology Inc
Balance Sheet Decomposition
CG Oncology Inc
Current Assets | 563.9m |
Cash & Short-Term Investments | 552.9m |
Receivables | 182k |
Other Current Assets | 10.8m |
Non-Current Assets | 466k |
PP&E | 413k |
Other Non-Current Assets | 53k |
Current Liabilities | 11.9m |
Accounts Payable | 4.5m |
Accrued Liabilities | 7.2m |
Other Current Liabilities | 131k |
Non-Current Liabilities | 118k |
Other Non-Current Liabilities | 118k |
Earnings Waterfall
CG Oncology Inc
Revenue
|
844k
USD
|
Operating Expenses
|
-104.6m
USD
|
Operating Income
|
-103.8m
USD
|
Other Expenses
|
139k
USD
|
Net Income
|
-103.6m
USD
|
Free Cash Flow Analysis
CG Oncology Inc
USD | |
Free Cash Flow | USD |
CGON Profitability Score
Profitability Due Diligence
CG Oncology Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
CG Oncology Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
CGON Solvency Score
Solvency Due Diligence
CG Oncology Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
CG Oncology Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGON Price Targets Summary
CG Oncology Inc
According to Wall Street analysts, the average 1-year price target for CGON is 69.07 USD with a low forecast of 52.52 USD and a high forecast of 90.3 USD.
Dividends
Current shareholder yield for CGON is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CG Oncology Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irvine, California and currently employs 61 full-time employees. The company went IPO on 2024-01-25. CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Contact
IPO
Employees
Officers
The intrinsic value of one CGON stock under the Base Case scenario is 56.11 USD.
Compared to the current market price of 35.01 USD, CG Oncology Inc is Undervalued by 38%.